title: Marketing of a new non-sedating antihistamine (fexofenadine) puts an additional burden on healthcare system resources in Israel.
authors.forename: Arnon D
authors.initials: AD
authors.lastname: Cohen
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Vardy
authors.forename: Uni
authors.initials: U
authors.lastname: Gan-El
authors.forename: Nicky
authors.initials: N
authors.lastname: Lieberman
authors.forename: Haim
authors.initials: H
authors.lastname: Reuvni
mesh_terms: D003132:Commerce / Q000639:trends; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D003695:Delivery of Health Care / Q000191:economics*; D011307:Drug Prescriptions / Q000191:economics; D039563:Histamine H1 Antagonists, Non-Sedating / Q000191:economics*; D006801:Humans; D007557:Israel; D017336:Loratadine / Q000191:economics; D008389:Marketing of Health Services / Q000191:economics*; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000191:economics
chemical_list: D039563:Histamine H1 Antagonists, Non-Sedating; D017336:Loratadine; D016593:Terfenadine; C093230:fexofenadine